Anti-inflammatory properties of fluticasone propionate.
Johnson
M
M
Glaxo Research and Development, Uxbridge, Middlesex, UK.
D000281:Administration, Intranasal; D000730:Androstadienes / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules / Q000378:metabolism; D002452:Cell Count / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004804:Eosinophils / Q000187:drug effects / Q000473:pathology; D000068298:Fluticasone; D006168:Guinea Pigs; D008264:Macrophages / Q000187:drug effects / Q000473:pathology; D012130:Respiratory Hypersensitivity / Q000188:drug therapy* / Q000473:pathology; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000473:pathology
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D015815:Cell Adhesion Molecules; D000068298:Fluticasone